Endoscopic Retrograde Cholangiopancreatography Market Report by Product, Procedure, End User, and Region 2024-2032
세계 내시경 역행 췌담관 조영술(ERCP) 시장 규모는 2023년 16억 달러에 달했습니다. 향후 IMARC 그룹은 2032년까지 시장이 2024-2032년간 5.88%의 연평균 성장률(CAGR)로 2032년까지 27억 달러에 달할 것으로 예측했습니다.
내시경 역행 췌담관 조영술(ERCP)은 간, 담낭, 담관 및 췌장의 이상을 진단하고 치료하는 영상 진단 기술로, 엑스레이와 식도, 입, 위를 통과하는 길고 유연하며 가벼운 내시경 튜브를 결합합니다. 담관 막힘, 결석, 감염, 종양, 췌장관의 체액 누출을 발견하는 데 도움이 됩니다. 또한 개복 수술보다 덜 침습적이며, 췌담도 계통에 대한 보다 상세하고 정확한 정보를 얻을 수 있습니다. 그 결과 연하장애, 설사, 체중 감소, 가슴앓이, 혈변 등을 조사하기 위한 내시경 치료 장비에 대한 수요가 전 세계적으로 증가하고 있습니다.
내시경 역행 췌담관 조영술(ERCP) 시장 동향 :
세계 인구 증가와 바렛병, 담도 질환, 간 질환, 크론병, 염증성 장 질환, 소화성 궤양 질환, 위식도 역류 질환(GERD) 등 다양한 만성 위장(GI) 질환과 지속적인 담도 질환의 유병률 증가는 시장에 긍정적인 영향을 미치는 주요 요인 중 하나입니다. 또한, 특히 노년층에서 양성 췌장암과 간암의 발생이 증가하고 있으며, 전 세계적으로 암 발생이 증가하고 있는 것도 시장을 견인하고 있습니다. 이에 따라 병원과 진단센터의 확대로 영상 진단 기술의 필요성이 증가하면서 시장 성장을 견인하고 있습니다. 또한, 첨단 내시경 장비 및 내시경 연구 개선을 위한 각국 정부 및 의료 기관의 투자 증가는 시장 성장을 강화하고 있습니다. 이와는 별도로, 빠른 회복과 최소 통증을 목표로 하는 최소 침습 수술에 대한 소비자 선호도의 변화와 괄약근 절개기와 같은 ERCP 장비에 대한 인식이 높아지면서 유리한 시장 전망을 제공합니다. 또한, 의료 인프라의 지속적인 개선과 의료 관광이 크게 증가하면서 시장 성장을 가속할 것으로 예상됩니다.
본 보고서에서 다룬 주요 질문
- 내시경 역행 췌담관 조영술(ERCP) 세계 시장 규모는?
- 2024-2032년 세계 내시경 역행 췌담관 조영술(ERCP) 시장의 예상 성장률은?
- 세계 내시경 역행 췌담관 조영술(ERCP) 시장을 이끄는 주요 요인은?
- 코로나19가 전 세계 내시경 역행 췌담관 조영술(ERCP) 시장에 미치는 영향은?
- 세계 내시경 역행 췌담관 조영술(ERCP) 시장의 제품별 시장 현황은?
- 세계 내시경 역행 췌담관 조영술(ERCP) 시장의 시술별 시장 현황은?
- 세계 내시경 역행 췌담관 조영술(ERCP) 시장의 최종 사용자별 분석은?
- 내시경 역행 췌담관 조영술(ERCP) 시장의 세계 주요 지역은?
- 세계 내시경적 역행성 담관 췌관 조영술 시장의 주요 기업은?
목차
제1장 서문
제2장 조사 범위와 조사 방법
- 조사 목적
- 이해관계자
- 데이터 소스
- 시장 추정
- 조사 방법
제3장 주요 요약
제4장 서론
제5장 세계의 내시경 역행 췌담관 조영술(ERCP)시장
- 시장 개요
- 시장 실적
- COVID-19의 영향
- 시장 예측
제6장 시장 분석 : 제품별
- 내시경
- 내시경 치료 기기
- 시각화 시스템
- 에너지 기기
- 기타
제7장 시장 분석 : 시술별
- 담도 괄약근 절개술
- 담관 스텐트
- 담관 확장증
- 췌괄약근 절개술
- 췌관 스텐트 유치술
- 췌관 확장
제8장 시장 분석 : 최종사용자별
제9장 시장 분석 : 지역별
- 북미
- 아시아태평양
- 유럽
- 독일
- 프랑스
- 영국
- 이탈리아
- 스페인
- 러시아
- 기타
- 라틴아메리카
- 중동 및 아프리카
제10장 SWOT 분석
제11장 밸류체인 분석
제12장 Porter의 Five Forces 분석
- 개요
- 바이어의 교섭력
- 공급 기업의 교섭력
- 경쟁 정도
- 신규 진출업체의 위협
- 대체품의 위협
제13장 가격 분석
제14장 경쟁 구도
- 시장 구조
- 주요 기업
- 주요 기업 개요
- Boston Scientific Corporation
- CONMED Corporation
- Cook Group Incorporated
- Fujifilm Holdings Corporation
- Hobbs Medical Inc.
- Johnson & Johnson
- Medi-Globe GmbH
- Medtronic plc
- Olympus Corporation
- Shaili Endoscopy
- Steris Corporation
- Telemed Systems Inc.
LSH
The global endoscopic retrograde cholangiopancreatography market size reached US$ 1.6 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 2.7 Billion by 2032, exhibiting a growth rate (CAGR) of 5.88% during 2024-2032.
Endoscopic retrograde cholangiopancreatography (ERCP) is an imaging technique that diagnoses and treats abnormalities in the liver, gallbladder, bile ducts, and pancreas. It combines X-rays and a long, flexible, lightweight endoscope tube that passes through the esophagus, mouth, and stomach. It helps detect blockages, stones, infections, and tumors in the bile duct and fluid leakage from the pancreatic duct. Besides this, it is a less invasive procedure than open surgery and provides more detailed and accurate information about the pancreaticobiliary system. As a result, the demand for endotherapy devices is increasing across the globe to investigate dysphagia, diarrhea, weight loss, heartburn, and stool blood.
Endoscopic Retrograde Cholangiopancreatography Market Trends:
The growing global population and the rising prevalence of various chronic gastrointestinal (GI) and incessant biliary medical disorders, including Barrett's disease, biliary, liver, Crohn's, inflammatory bowel, and peptic ulcer disease, and gastroesophageal reflux disorder (GERD), represent one of the key factors positively influencing the market. In addition, the increasing occurrence of benign pancreas and liver tumors, especially among the geriatric population, along with the growing occurrence of cancer across the globe, is driving the market. In line with this, the expansion of hospitals and diagnostic centers is increasing the need for imaging techniques propelling the market growth. Furthermore, rising investments by governments and healthcare organizations of various countries in advanced endoscopy devices and improve endoscopy research is strengthening the market growth. Apart from this, the shifting consumer preference toward minimally invasive surgeries for a speedy recovery and minimal pain and rising awareness about ERCP devices like sphincterotomes are offering a favorable market outlook. Moreover, continuous improvements in healthcare infrastructure and a considerable rise in medical tourism are expected to propel market growth.
Key Market Segmentation:
IMARC Group provides an analysis of the key trends in each sub-segment of the global endoscopic retrograde cholangiopancreatography market report, along with forecasts at the global, regional and country level from 2024-2032. Our report has categorized the market based on product, procedure and end user.
Breakup by Product:
Endoscope
Endotherapy Devices
Sphincterotomes
Lithotripter
Stents
Others
Visualization Systems
Energy Devices
Others
Breakup by Procedure:
Biliary Sphincterotomy
Biliary Stenting
Biliary Dilatation
Pancreatic Sphincterotomy
Pancreatic Duct Stenting
Pancreatic Duct Dilatation
Breakup by End User:
Hospitals and Clinics
Ambulatory Surgery Centers
Others
Breakup by Region:
North America
United States
Canada
Asia-Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa
Competitive Landscape:
The competitive landscape of the industry has also been examined along with the profiles of the key players being Boston Scientific Corporation, CONMED Corporation, Cook Group Incorporated, Fujifilm Holdings Corporation, Hobbs Medical Inc., Johnson & Johnson, Medi-Globe GmbH, Medtronic plc, Olympus Corporation, Shaili Endoscopy, Steris Corporation and Telemed Systems Inc.
Key Questions Answered in This Report
- 1. How big is the global endoscopic retrograde cholangiopancreatography market?
- 2. What is the expected growth rate of the global endoscopic retrograde cholangiopancreatography market during 2024-2032?
- 3. What are the key factors driving the global endoscopic retrograde cholangiopancreatography market?
- 4. What has been the impact of COVID-19 on the global endoscopic retrograde cholangiopancreatography market?
- 5. What is the breakup of the global endoscopic retrograde cholangiopancreatography market based on the product?
- 6. What is the breakup of the global endoscopic retrograde cholangiopancreatography market based on the procedure?
- 7. What is the breakup of the global endoscopic retrograde cholangiopancreatography market based on the end user?
- 8. What are the key regions in the global endoscopic retrograde cholangiopancreatography market?
- 9. Who are the key players/companies in the global endoscopic retrograde cholangiopancreatography market?
Table of Contents
1 Preface
2 Scope and Methodology
- 2.1 Objectives of the Study
- 2.2 Stakeholders
- 2.3 Data Sources
- 2.3.1 Primary Sources
- 2.3.2 Secondary Sources
- 2.4 Market Estimation
- 2.4.1 Bottom-Up Approach
- 2.4.2 Top-Down Approach
- 2.5 Forecasting Methodology
3 Executive Summary
4 Introduction
- 4.1 Overview
- 4.2 Key Industry Trends
5 Global Endoscopic Retrograde Cholangiopancreatography Market
- 5.1 Market Overview
- 5.2 Market Performance
- 5.3 Impact of COVID-19
- 5.4 Market Forecast
6 Market Breakup by Product
- 6.1 Endoscope
- 6.1.1 Market Trends
- 6.1.2 Market Forecast
- 6.2 Endotherapy Devices
- 6.2.1 Market Trends
- 6.2.2 Key Segments
- 6.2.2.1 Sphincterotomes
- 6.2.2.2 Lithotripter
- 6.2.2.3 Stents
- 6.2.2.4 Others
- 6.2.3 Market Forecast
- 6.3 Visualization Systems
- 6.3.1 Market Trends
- 6.3.2 Market Forecast
- 6.4 Energy Devices
- 6.4.1 Market Trends
- 6.4.2 Market Forecast
- 6.5 Others
- 6.5.1 Market Trends
- 6.5.2 Market Forecast
7 Market Breakup by Procedure
- 7.1 Biliary Sphincterotomy
- 7.1.1 Market Trends
- 7.1.2 Market Forecast
- 7.2 Biliary Stenting
- 7.2.1 Market Trends
- 7.2.2 Market Forecast
- 7.3 Biliary Dilatation
- 7.3.1 Market Trends
- 7.3.2 Market Forecast
- 7.4 Pancreatic Sphincterotomy
- 7.4.1 Market Trends
- 7.4.2 Market Forecast
- 7.5 Pancreatic Duct Stenting
- 7.5.1 Market Trends
- 7.5.2 Market Forecast
- 7.6 Pancreatic Duct Dilatation
- 7.6.1 Market Trends
- 7.6.2 Market Forecast
8 Market Breakup by End User
- 8.1 Hospitals and Clinics
- 8.1.1 Market Trends
- 8.1.2 Market Forecast
- 8.2 Ambulatory Surgery Centers
- 8.2.1 Market Trends
- 8.2.2 Market Forecast
- 8.3 Others
- 8.3.1 Market Trends
- 8.3.2 Market Forecast
9 Market Breakup by Region
- 9.1 North America
- 9.1.1 United States
- 9.1.1.1 Market Trends
- 9.1.1.2 Market Forecast
- 9.1.2 Canada
- 9.1.2.1 Market Trends
- 9.1.2.2 Market Forecast
- 9.2 Asia-Pacific
- 9.2.1 China
- 9.2.1.1 Market Trends
- 9.2.1.2 Market Forecast
- 9.2.2 Japan
- 9.2.2.1 Market Trends
- 9.2.2.2 Market Forecast
- 9.2.3 India
- 9.2.3.1 Market Trends
- 9.2.3.2 Market Forecast
- 9.2.4 South Korea
- 9.2.4.1 Market Trends
- 9.2.4.2 Market Forecast
- 9.2.5 Australia
- 9.2.5.1 Market Trends
- 9.2.5.2 Market Forecast
- 9.2.6 Indonesia
- 9.2.6.1 Market Trends
- 9.2.6.2 Market Forecast
- 9.2.7 Others
- 9.2.7.1 Market Trends
- 9.2.7.2 Market Forecast
- 9.3 Europe
- 9.3.1 Germany
- 9.3.1.1 Market Trends
- 9.3.1.2 Market Forecast
- 9.3.2 France
- 9.3.2.1 Market Trends
- 9.3.2.2 Market Forecast
- 9.3.3 United Kingdom
- 9.3.3.1 Market Trends
- 9.3.3.2 Market Forecast
- 9.3.4 Italy
- 9.3.4.1 Market Trends
- 9.3.4.2 Market Forecast
- 9.3.5 Spain
- 9.3.5.1 Market Trends
- 9.3.5.2 Market Forecast
- 9.3.6 Russia
- 9.3.6.1 Market Trends
- 9.3.6.2 Market Forecast
- 9.3.7 Others
- 9.3.7.1 Market Trends
- 9.3.7.2 Market Forecast
- 9.4 Latin America
- 9.4.1 Brazil
- 9.4.1.1 Market Trends
- 9.4.1.2 Market Forecast
- 9.4.2 Mexico
- 9.4.2.1 Market Trends
- 9.4.2.2 Market Forecast
- 9.4.3 Others
- 9.4.3.1 Market Trends
- 9.4.3.2 Market Forecast
- 9.5 Middle East and Africa
- 9.5.1 Market Trends
- 9.5.2 Market Breakup by Country
- 9.5.3 Market Forecast
10 SWOT Analysis
- 10.1 Overview
- 10.2 Strengths
- 10.3 Weaknesses
- 10.4 Opportunities
- 10.5 Threats
11 Value Chain Analysis
12 Porters Five Forces Analysis
- 12.1 Overview
- 12.2 Bargaining Power of Buyers
- 12.3 Bargaining Power of Suppliers
- 12.4 Degree of Competition
- 12.5 Threat of New Entrants
- 12.6 Threat of Substitutes
13 Price Analysis
14 Competitive Landscape
- 14.1 Market Structure
- 14.2 Key Players
- 14.3 Profiles of Key Players
- 14.3.1 Boston Scientific Corporation
- 14.3.1.1 Company Overview
- 14.3.1.2 Product Portfolio
- 14.3.1.3 Financials
- 14.3.1.4 SWOT Analysis
- 14.3.2 CONMED Corporation
- 14.3.2.1 Company Overview
- 14.3.2.2 Product Portfolio
- 14.3.2.3 Financials
- 14.3.2.4 SWOT Analysis
- 14.3.3 Cook Group Incorporated
- 14.3.3.1 Company Overview
- 14.3.3.2 Product Portfolio
- 14.3.4 Fujifilm Holdings Corporation
- 14.3.4.1 Company Overview
- 14.3.4.2 Product Portfolio
- 14.3.4.3 Financials
- 14.3.4.4 SWOT Analysis
- 14.3.5 Hobbs Medical Inc.
- 14.3.5.1 Company Overview
- 14.3.5.2 Product Portfolio
- 14.3.6 Johnson & Johnson
- 14.3.6.1 Company Overview
- 14.3.6.2 Product Portfolio
- 14.3.6.3 Financials
- 14.3.6.4 SWOT Analysis
- 14.3.7 Medi-Globe GmbH
- 14.3.7.1 Company Overview
- 14.3.7.2 Product Portfolio
- 14.3.8 Medtronic plc
- 14.3.8.1 Company Overview
- 14.3.8.2 Product Portfolio
- 14.3.8.3 Financials
- 14.3.8.4 SWOT Analysis
- 14.3.9 Olympus Corporation
- 14.3.9.1 Company Overview
- 14.3.9.2 Product Portfolio
- 14.3.9.3 Financials
- 14.3.9.4 SWOT Analysis
- 14.3.10 Shaili Endoscopy
- 14.3.10.1 Company Overview
- 14.3.10.2 Product Portfolio
- 14.3.11 Steris Corporation
- 14.3.11.1 Company Overview
- 14.3.11.2 Product Portfolio
- 14.3.12 Telemed Systems Inc.
- 14.3.12.1 Company Overview
- 14.3.12.2 Product Portfolio
